- Home
- GNPX vs NCI Comparison
GNPX vs NCI Comparison
Compare GNPX & NCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- NCI
- Stock Information
- Founded
- GNPX 2009
- NCI 1992
- Country
- GNPX United States
- NCI Hong Kong
- Employees
- GNPX N/A
- NCI N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- NCI
- Sector
- GNPX Health Care
- NCI
- Exchange
- GNPX Nasdaq
- NCI NYSE
- Market Cap
- GNPX 6.6M
- NCI 7.4M
- IPO Year
- GNPX 2018
- NCI 2024
- Fundamental
- Price
- GNPX $0.28
- NCI $2.02
- Analyst Decision
- GNPX
- NCI
- Analyst Count
- GNPX 0
- NCI 0
- Target Price
- GNPX N/A
- NCI N/A
- AVG Volume (30 Days)
- GNPX 3.4M
- NCI 164.9K
- Earning Date
- GNPX 08-08-2025
- NCI 07-22-2025
- Dividend Yield
- GNPX N/A
- NCI N/A
- EPS Growth
- GNPX N/A
- NCI 67.70
- EPS
- GNPX N/A
- NCI 0.26
- Revenue
- GNPX N/A
- NCI $30,340,230.00
- Revenue This Year
- GNPX N/A
- NCI N/A
- Revenue Next Year
- GNPX N/A
- NCI N/A
- P/E Ratio
- GNPX N/A
- NCI $8.54
- Revenue Growth
- GNPX N/A
- NCI 35.28
- 52 Week Low
- GNPX $0.20
- NCI $1.40
- 52 Week High
- GNPX $3.97
- NCI $9.00
- Technical
- Relative Strength Index (RSI)
- GNPX 55.29
- NCI N/A
- Support Level
- GNPX $0.25
- NCI N/A
- Resistance Level
- GNPX $0.27
- NCI N/A
- Average True Range (ATR)
- GNPX 0.03
- NCI 0.00
- MACD
- GNPX 0.00
- NCI 0.00
- Stochastic Oscillator
- GNPX 90.71
- NCI 0.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company that is a one-stop apparel solution services provider. The company offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European and North American markets.